Non-Compliance by Indian Drug Manufacturer: Cross Contamination
Recommendation

16-18 June 2026
Good Engineering Practice for Pharmaceutical Companies and Suppliers
So-called Non-Compliance reports are summaries of inspections conducted by European inspectors. They are publicly available on the EMA’s (European Medicines Agency) website. In the present case, the Non-Compliance Report is based on the inspection of an Indian pharmaceutical manufacturer in Bangalore, which was conducted by the MHRA in November 2017.
The report concerns the manufacturing of non-sterile dosage forms: tablets and capsules as well as their primary and secondary packaging. The inspectors found the cleaning procedure and the proof of cleaning success during product changes to be inadequate. As a result of the inspection, the GMP certificate was withdrawn. Due to the severity of the deficiencies found and the resulting cross contamination risk, the MHRA recommends a precautionary recall of all affected batches in the market.
Source: EudraGMDP Database
Related GMP News
08.04.2026Deficiencies in Equipment Design lead to Warning Letter
01.04.2026Rouging in pharmaceutical Water and Pure Steam Systems: Causes, Effects and Control Measures
18.03.2026HVAC Systems: Is there a Difference between Mixed Air and Recirculation Air Operation?
04.03.2026Warning Letter to US Contract Manufacturer of OTC Drugs due to Cross-Contamination Risk
04.03.2026Warning Letter following Complaints about Tablets
04.03.2026What does the FDA expect regarding Facility Maintenance?


